PubMed Health⌕ Search

Biomedical subjects

I Bodrogi

Publications and source records attributed to I Bodrogi.

At least 55 records · Page 3Linked to original sources
PubMed1990

Persistence of chromosomal aberrations in blood lymphocytes of testicular cancer patients. I. The effect of vinblastine, cisplatin and bleomycin adjuvant therapy.

Chromosomal aberrations and sister chromatid exchanges were examined in 45 patients with nonseminomatous testicular cancer at different times after the termination of vinblastine, cisplatin and bleomycin (VPB) therapy and in 22 age-matched healthy men and untreated testicular cancer patients. After 36 months, the frequency of unstable aberrations markedly decreased in peripheral blood lymphocytes of VPB-treated patients, however the persistence of aberrant cells even 75 months after the termination of treatment underlines the necessity of longer follow-up of VPB-treated patients in order to evaluate the relationship between their carcinogen sensitivity and the risk of second malignancies.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1990

Vinblastine, cisplatin and bleomycin treatment of advanced nonseminomatous testicular tumors.

Between December 1979 and July 1986, 190 patients with nonseminomatous germ-cell testicular tumors were treated according to the modified Einhorn scheme. The response rate was 67.89%. The most favorable results were found in the embryonal histologic type (RR = 76.9%), in the biological marker (AFP, HCG) negative (RR = 97.43%) and in the minimal pulmonary extent group (RR = 94.12%).

Adolescent↗
PubMed1989

[Combined therapy of malignant testicular tumors].

The 5-year survival of patients with malignant testicular tumors rose during the past 25 years from 10-25% depending on stage to 55-100% after radical castration performed from high inguinal opening, retroperitoneal lymphadenectomy, ultra-tension irradiation and adjuvant chemotherapy. It is stressed that patients diagnosed at stage T1-2, N0-2, M0 may even recover perfectly upon complex therapy. Three to five-year long or even longer survival may be reached with 50% of the patients at the stage T1-3, N1-3, M1. Patients at stage T4, N3-4, M1 die because of the recurrence of the tumor and/or the complication of the adjuvant treatment within 1-3 years and even the interdisciplinary work which is very effective in other stages fails to change this at the present time.

Combined Modality Therapy↗
PubMed1989

Vinblastine, cisplatin and bleomycin (VPB) adjuvant therapy does not induce dose-dependent damage in human chromosomes.

Chromosome aberrations and sister chromatid exchanges were examined in testicular tumor patients treated by 4 cycles of vinblastine, cisplatin and bleomycin adjuvant therapy. The predominant aberrations in cells varied among the patients, and due to interindividual variability no time- or dose-dependent changes were observed in cytogenetic data. There was found an overdispersion of aberrations which might be explained by the effect of bleomycin. Sister chromatid exchange (SCE) frequency was slightly increased and showed also an individual variability in the response to vinblastine, cisplatin and bleomycin (VPB) therapy. No correlation with chromosome aberration rate was found. Further data are required for the real estimation of long-term effects of VPB therapy.

Adolescent↗
PubMed1989

Third-line chemotherapy of resistant advanced testicular cancer.

The efficacy of combined chemotherapy of Vepesid + Holoxan +/- Adriblastin as third-choice was studied in advanced testicular cancer patients refractory to or recurrent after first- and second-line cytostatic therapy. Between September 1981 and January 1988 49 evaluable patients were treated with Vepesid (VP-16213 - 100 mg/m2 days 1-5), Holoxan (40 mg/kg days 1-5), hydration, urine alkylation + Uromitexan +/- Adriblastin (40 mg/m2 day 1). The single dose of Uromitexan was 20% of the daily dose of Holoxan, and the patients received it i.v. just prior to Holoxan administration (hr 0), then 4 and 8 hrs later. Two patients got into CR and 10 to PR. The rate of remission was 24.48%. The most severe side effect was leukopenia. The elevation of CN and Se creatinine was transient and mild. In those cases where Holoxan was not included in the first or second-line regimens, when combined with Vepesid and Adriblastin as third-choice therapy one could achieve further improvement. In case of CR the prolongation of life is also noteworthy.

Adult↗
PubMed1988

Ifosfamide chemotherapy of metastatic renal cell cancer.

In view of the divergent reports on the efficacy of ifosfamide in metastatic renal cell cancer, we tested this drug as monotherapy in nine patients on a dosage schedule of intravenous infusion of 40 mg/kg per day on days 1-5, repeated every 4 wk. The drug was administered in 1 liter saline dextrose over 2 hr, with hydration, alkalization of the urine, and mesna. No objective response was registered and subjective response in three patients was of short duration. The number of patients in this series is too small to draw definitive conclusions. However, the results obtained in this study does not prove antitumor activity for ifosfamide in renal cell cancer.

Adult↗
PubMed1985

Characteristics and chemotherapeutic sensitivity of a human testicular cancer grown in artificially immunosuppressed mice.

Seven human testicular tumors were transplanted into artificially immunosuppressed mice. Two of them grew progressively (TT2 and TT6) and a serially transplantable line was developed from TT2. The xenografts maintained only the embryonal carcinoma components of originally mixed (embryonal cell carcinoma and choriocarcinoma) donor tumor. Although the histology did not change remarkably with passages, the xenografts lost their capacity to express human choriogonadotropin and alpha-fetoprotein. The latency period shortened, the growth rate remained similar with subsequent transplantations. The tumor cells of the TT2 line presented the human character according to chromosome analysis and were built up of two subsets of cells with a different DNA index estimated by flow cytometry. The embryonal cell carcinoma line was highly sensitive to CY and cisDDP. PVB combination was also effective, although the tumor growth inhibition proved to be only temporary.

Adult↗
PubMed1980

Forms and results of mitolactol therapy.

The authors give a summarizing report about mitolactol treatments performed in Hungary. As a single-agent therapy the drug was administered in two forms: (1) every-day therapy, 5 mg/kg/day, (2) push therapy, 10 mg/kg every 5th day or 15 mg/kg every 7th day, in a total dose of 100 mg/kg in both administration forms. Out of the solid tumours the squamous cell cancers proved to be the most responsive to mitolactol therapy: first of all in tumours of the head and neck and of the lung. The study also reports the preliminary results of polychemotherapeutical protocols containing mitolactol now in progress: (1) bleomycin + mitolactol (Bristol protocol), (2) carminomycin + mitolactol and (3) adriamycin + mitolactol.

Dose-Response Relationship, Drug↗
PubMed1975

Results obtained with combination therapy of VM-26, natulan and prednisolone in generalized Hodgkin's disease.

By evaluating the results obtained in 50 patients the authors stated that VM-26 given in combination with Natulan and Prednisolone is a drug of value in the therapy of generalized Hodgkin's disease. It cause milder side effects than drugs previously used in combination therapy. Complete or partial remissions were obtained in 84% of patients treated. 75% of the therapy-resistant cases proved to be Hodgkin's sarcoma by the postmortem examination. Remission lasted longer in stage III than in stage IV and the previously untreated patients responded better than the treated one. Definite correlation could not be revealed between histologic type and duration of remission.

Adolescent↗
PubMed1975

Vitiligo and malignant melanoma.

Six patients with vitiligo and malignant melanoma are reported. The relationship between vitiligo and melanoma seems to be a firm one. This process is supposed to represent an expression of induced autoimmunity.

Aged↗
PubMedDate not supplied

mdm-2 expression in human testicular germ-cell tumors and its clinical value.

BACKGROUND: In germ cell testicular tumors (GCTT) mdm-2 gene was analyzed for amplification and transcripts but not for protein. The purpose of this study is to determine whether mdm-2 protein level is aberrant in GCTT and if so, what is the relationship between mdm-2 overexpression and other disease parameters including histologic subtypes, p53 status, metastatic potential and clinical stage. METHODS: 81 testicular germ-cell tumors were screened for their mdm-2 expression at the protein levels using immunohistochemistry (IHC) and Western blot (WB) analysis. RESULTS: Of 81 GCTTs 45 (55.55%) showed mdm-2 nuclear immunoreactivity, 34 (41.97%) of which were strongly positive. The incidence of mdm-2 immunostaining was significantly higher (P = 0.0007) in non-seminomas (NSGCT) than in seminomas (SGCT). The frequency of positive tumor was higher in tumors from metastatic patients than in tumors from metastatic-free patients (P = 0.011). mdm-2 expression was detected significantly more frequently in tumors of advanced stages, i.e. IIB, IIC and III versus tumors of early stages (I and II/A) (P = 0.0098). A significant difference between the three stages of disease as to the expression of mdm-2 (chi 2 = 0.0386) could be established, namely the incidence of mdm-2 expression increased with an increase in stage. Using Westem blotting 22 (68.75%) out of 32 tumors overexpressed the mdm-2 oncoprotein of 90 kd (p90). CONCLUSIONS: mdm-2 expression as detected by immunohistochemistry may provide a reliable prognostic tool to isolate subgroups of patients with more aggressive GCTT.

Adolescent↗